Praxis Precision Medicines Files 8-K

TL;DR

Praxis Precision Medicines dropped an 8-K on Jan 29th covering Jan 12th results. Check it for financial deets.

AI Summary

Praxis Precision Medicines, Inc. filed an 8-K on January 29, 2025, reporting on events that occurred on January 12, 2025. The filing pertains to results of operations and financial condition, as well as financial statements and exhibits. The company is incorporated in Delaware and headquartered in Boston, Massachusetts.

Why It Matters

This 8-K filing provides an update on Praxis Precision Medicines' operational and financial status, which is crucial for investors to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of operational and financial information, not indicating any immediate significant risks.

Key Players & Entities

• Praxis Precision Medicines, Inc. (company) — Registrant
• January 12, 2025 (date) — Earliest event reported
• January 29, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• Boston, Massachusetts (location) — Principal executive offices
• 001-39620 (commission_file_number) — SEC File Number

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share PRAX The Nasdaq Glo

Filing Documents

• prax-20250112.htm (8-K) — 34KB
• a8-kexhibit991.htm (EX-99.1) — 38KB
• image_0.jpg (GRAPHIC) — 11KB
• 0001689548-25-000021.txt ( ) — 221KB
• prax-20250112.xsd (EX-101.SCH) — 2KB
• prax-20250112_lab.xml (EX-101.LAB) — 22KB
• prax-20250112_pre.xml (EX-101.PRE) — 13KB
• prax-20250112_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 12, 2025, Praxis Precision Medicines, Inc. (the "Company") issued a press release announcing, among other things, the Company's preliminary unaudited cash, cash equivalents and marketable securities balance as of December 31, 2024. The full text of the press release issued by the Company is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly provided by specific reference in such a filing. Financial Disclosure Advisory Exhibit 99.1 contains certain estimated preliminary financial information as of December 31, 2024, which is based on the information available to the Company at this time. The Company's financial closing procedures for the fourth quarter and full year 2024 are not yet complete and, as a result, actual results may vary from the estimated preliminary information presented here due to the completion of the Company's financial closing and audit procedures. The estimated preliminary financial information has not been audited or reviewed by the Company's independent registered public accounting firm and should not be viewed as a substitute for the Company's full annual financial statements. Accordingly, you should not place undue reliance on this preliminary data.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release date d January 12, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRAXIS PRECISION MEDICINES, INC. Date: January 29, 2025 By: /s/ Marcio Souza Marcio Souza Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR